case_images: PMC9755882_01
case_images: Coronal reformatted PET image before and after treatment initiation. Figure 1 (left) shows two hypermetabolic liver lesions. Figure 2 (right) shows complete response of both lesions.
case_images: fonc-12-997346-g001.jpg
case_images: PMC9755882_01_fonc-12-997346-g001.jpg
case_images: f1
case_images: First imaging reevaluation was performed in June, 2021 using a CT-PET scan that showed hepatic and bone complete response ( Figures 1 ,  2 ).
case_images: Sagittal reformatted PET image before and after treatment initiation. Multiple foci of intense bone uptake are shown in figure 3 (left). Figure 4 (right) shows metabolic response of every lesion.
case_images: fonc-12-997346-g002.jpg
case_images: PMC9755882_01_fonc-12-997346-g002.jpg
case_images: f2
case_images: First imaging reevaluation was performed in June, 2021 using a CT-PET scan that showed hepatic and bone complete response ( Figures 1 ,  2 ).
case_images: Mutant allele frequency of BRAF V600E mutation in plasma during treatment.
case_images: fonc-12-997346-g003.jpg
case_images: PMC9755882_01_fonc-12-997346-g003.jpg
case_images: f3
case_images: Mutation assay (Biocartis ) ( Figure 3 ). Mutant allele frequency (MAF) of 16.9% was detected before start the dabrafenib/trametinib treatment.